2
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Lung Neoplasms
5
Glioma
3
Glioblastoma
3
Carcinoma, Non-Small-Cell Lung
3
Breast Neoplasms
3
Head and Neck Neoplasms
2
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Urethral Neoplasms
1
Ureteral Neoplasms
1
Sarcoma
1
Rhabdomyosarcoma
1
Prostatic Neoplasms
1
Pheochromocytoma
1
Paraganglioma
1
Papillary renal cell carcinoma, sporadic
1
Pancreatic Neoplasms
1
Pancreatic Ductal Adenocarcinoma
1
Osteoradionecrosis
1
Neurotoxicity Syndromes
1
Myelodysplastic Syndromes
1
Multiple Myeloma
1
Mouth Neoplasms
1
Melanoma
1
Lymphoma, B-Cell
1
Leukemia, Myeloid, Acute
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Hereditary leiomyomatosis and renal cell cancer
1
Hematopoietic and Lymphoid System Neoplasm
1
Healthy Volunteers
1
Interventions
Rituximab
112
Cyclophosphamide
103
fludarabine
61
Doxorubicin
33
Vincristine
31
Etoposide
31
Prednisone
30
Lenalidomide
24
ibrutinib
22
fludarabine phosphate
21
Immunotherapy, Adoptive
19
Bendamustine Hydrochloride
19
obinutuzumab
18
Cytarabine
18
pembrolizumab
16
Magnetic Resonance Spectroscopy
16
Bortezomib
14
Specimen Handling
13
Dexamethasone
13
polatuzumab vedotin
12
CT-P10
12
venetoclax
11
Gemcitabine
11
Carboplatin
11
pirtobrutinib
10
glofitamab
10
zanubrutinib
9
Nivolumab
9
Mycophenolic Acid
9
Melphalan
9
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Lymphoma, B-Cell
×
Contrast Media
×
Clear all
NCT05510596
2024-08-09
MR-ICANS
University Hospital, Montpellier
Phase NA
Completed
25 enrolled